LCKLSL acetate 是一种竞争性膜联蛋白 A2 (AnxA2) 抑制剂。 LCKLSL acetate 有效抑制组织纤溶酶原激活剂 (tPA) 与 AnxA2 的结合和纤溶酶的产生。 LCKLSL acetate 具有抗血管生成作用。

LCKLSL acetate is a competitive annexin A2 (AnxA2) inhibitor. LCKLSL acetate potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2 and the generation of plasmin. LCKLSL acetate has anti-angiogenic roles.

LCKLSL acetate (0-2 mg) inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions in human retinal microvascular endothelial cells (RMVECs)[1].

In chicken chorioallantoic membrane and murine Matrigel plug assays, LCKLSL acetate significantly decreased the vascular length. LCKLSL acetate(5 μg/mL) significantly decreased the number of vascular branches, junctions and end-points[1].

TP2482

C32H61N7O10S

735.93

LCKLSL acetate(533902-29-3 free base)

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years